MicroRNA-100 promotes migration and invasion through mammalian target of rapamycin in esophageal squamous cell carcinoma

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1409-1418

  Zhang, Naijian ^a,b   Fu, Hailong ^a,c   Song, Leilei ^a   Ding, Youhong ^a   Wang, Xiufang ^a,b   Zhao, Chao ^a   Zhao, Yiqi ^a   Jiao, Feng ^a   Zhao, Yaping ^a  

^a The 82nd Hospital of the People's Liberation Army   (China)

^b BENGBU MEDICAL COLLEGE   (China)

^c JIANGSU UNIVERSITY   (China)

Author keywords

Bioinformatic analysis; Esophageal squamous cell carcinoma; Invasion; Metastasis; microRNA; miR 100

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 100; 3' UNTRANSLATED REGION; MICRORNA; MIRN100 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ECA109 CELL LINE; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TE 1 CELL LINE; TUMOR SUPPRESSOR GENE; WOUND HEALING; CELL MOTION; ESOPHAGUS TUMOR; GENETICS; HEPG2 CELL LINE; HT 29 CELL LINE; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HT29 CELLS; HUMANS; LYMPH NODES; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; TOR SERINE-THREONINE KINASES;

EID: 84916642069     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3389     Document Type: Article

References (41)

1. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003. (Pubitemid 37485141)
2. Orringer MB: Multimodality therapy for esophageal carcinoma - update. Chest 103: 406S-409S, 1993.
3. Rice TW, Rusch VW, Apperson-Hansen C, et al: Worldwide esophageal cancer collaboration. Dis Esophagus 22: 1-8, 2009.
4. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
5. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
6. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
7. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
8. Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M: microRNAs in cancer management. Lancet Oncol 13: e249-e258, 2012.
9. Jia XQ, Cheng HQ, Qian X, et al: Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma. Cell Biochem Biophys 62: 237-244, 2012.
10. Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004. (Pubitemid 38327724)
11. Kong KL, Kwong DL, Chan TH, et al: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61: 33-42, 2012.
12. Zhang HF, Zhang K, Liao LD, et al: miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma cells via targeting Kindlin-2. Carcinogenesis 35: 292-301, 2014.
13. Fu HL, Wu de P, Wang XF, et al: Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China. Cell Biochem Biophys 67: 657-668, 2013.
14. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH and Srougi M: MicroRNA expression profiles in the progression of prostate cancer - from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31: 796-801, 2013.
15. Feng B, Wang R and Chen LB: MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317: 184-191, 2012
16. Zheng YS, Zhang H, Zhang XJ, et al: MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 31: 80-92, 2012.
17. Peng DX, Luo M, Qiu LW, He YL and Wang XF: Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 27: 1238-1244, 2012.
18. Oliveira JC, Brassesco MS, Morales AG, et al: MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev 12: 3001-3004, 2011.
19. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E and Gollin SM: Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 48: 569-582, 2009.
20. Gebeshuber CA and Martinez J: miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene 32: 3306-3310, 2013.
21. Zhu Q, Hong A, Sheng N, et al: microParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol 382: 287-312, 2007.
22. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T and Zamore PD: A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293: 834-838, 2001. (Pubitemid 32743968)
23. Alvarez-Garcia I and Miska EA: MicroRNA functions in animal development and human disease. Development 132: 4653-4662, 2005. (Pubitemid 41685276)
24. Hiyoshi Y, Kamohara H, Karashima R, et al: MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 15: 1915-1922, 2009.
25. Guo Y, Chen Z, Zhang L, et al: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68: 26-33, 2008. (Pubitemid 351380102)
26. Smith CM, Watson DI, Michael MZ and Hussey DJ: MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol 16: 531-537, 2010.
27. Kinoshita T, Hanazawa T, Nohata N, et al: Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget 3: 1386-1400, 2012.
28. Majid S, Dar AA, Saini S, et al: MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 7: e46743, 2012.
29. Liu W, Gong YH, Chao TF, et al: Identification of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas. Chin Med J 122: 2405-2411, 2009.
30. Li BH, Zhou JS, Ye F, Cheng XD, Zhou CY, Lu WG and Xie X: Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer 47: 2166-2174, 2011.
31. Hildebrandt MA, Yang H, Hung MC, et al: Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871, 2009.
32. Oyama K, Okawa T, Nakagawa H, et al: AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene 26: 2353-2364, 2007. (Pubitemid 46572817)
33. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK and Nakagawa H: Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275: 30934-30942, 2000.
34. Baba Y, Iyama KI, Hirashima K, et al: Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation. Br J Cancer 98: 974-980, 2008. (Pubitemid 351341610)
35. Li B, Tsao SW, Li YY, et al: Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer 125: 2576-2585, 2009.
36. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004. (Pubitemid 39071573)
37. Kim JE and Chen J: Cytoplasmic-nuclear shuttling of FKBP12- rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA 97: 14340-14345, 2000. (Pubitemid 32016577)
38. Martin DE and Hall MN: The expanding TOR signaling network. Curr Opin Cell Biol 17: 158-166, 2005. (Pubitemid 40380939)
39. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058, 2005. (Pubitemid 41161231)
40. Treeck O, Wackwitz B, Haus U and Ortmann O: Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102: 292-299, 2006. (Pubitemid 44041641)
41. DeGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10: 8059-8067, 2004. (Pubitemid 39587547)